Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE III versus ASBRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE III versus ASBRON.
AEROLATE III vs ASBRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
None Documented
None Documented
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Category C
Category C
Bronchodilator
Bronchodilator